Skip to content

Clinical trials

Bronchopulmonary Dysplasia trials in the United States with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Bronchopulmonary Dysplasia Phase: Not applicable Country / region: United States Clear all

45 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20072
20081
20111
20122
20142
20152
20162
20174
20183
20191
20202
20215
20224
20234
20242
20253
20264

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed21
Recruiting10
Terminated9
Active, not recruiting3
Not yet recruiting1
Unknown status1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Children's Hospital of Philadelphia6
University of Alabama at Birmingham4
NICHD Neonatal Research Network3
University of Florida2
University of Texas Southwestern Medical Center2
Arkansas Children's Hospital Research Institute1
Baylor College of Medicine1
Baystate Medical Center1
Boston Children's Hospital1
Christiana Care Health Services1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Bronchopulmonary Dysplasia45
Premature Birth20
Respiratory Distress Syndrome4
Apnea3
Respiratory Distress Syndrome, Newborn3
Asthma2
Gastroesophageal Reflux2
Hypoxia2
Infant, Newborn, Diseases2
Infant, Premature, Diseases2

Trials

Showing 1 to 25 of 45. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.